Table III.

Modulation of EAE by α-GalCer in C57BL/6 and C57BL/6.CD1d^−/− Mice

Treatment	No. animals with EAE/total no. of animals (individual maximal score)	Mean disease score	Mean day of onset
C57BL/6 mice
Vehicle/PBS	9/10 (5,5,4,4,4,4,3,1,1,0)	3.1	14.4
Coimmunization with α-GalCer	2/10 (2,1,0,0,0,0,0,0,0,0)	0.3	13.5
C57BL/6.CD1d−/− mice
Vehicle/PBS	10/12 (4,3,3,3,3,2,2,2,1,1,0,0)	2.0	14.9
Coimmunization with α-GalCer	7/8 (4,3,2,2,2,2,1,0)	2.0	16.6

Groups of age-matched mice were subcutaneously immunized with 300 μg of MOG35–55 emulsified in CFA and at the same time administered with 4.4 μg of α-GalCer in vehicle or with the vehicle only, as described in Materials and Methods. Clinical symptoms of EAE were monitored daily.